Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03858543 · ClinicalTrials.gov registry record · Early Phase 1
Fractional Laser Assisted Delivery of Sculptra® for the Treatment of Striae
A Early Phase 1 study of Striae Distensae, sponsored by Henry Ford Health System.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT03858543: Completed Early Phase 1 study of Striae Distensae, sponsored by Henry Ford Health System.
NCT03858543 is a Early Phase 1 study of Striae Distensae that has completed, run by Henry Ford Health System. The registered enrollment target is 10 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03858543, a Early Phase 1 study of Striae Distensae, has completed, sponsored by Henry Ford Health System.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
This study evaluates the efficacy of treatment of striae distensae using the combined modality of fractional laser and poly-L lactic acid (Sculptra).
Primary Outcome
Modified Manchester Scar Scale was used to assess stretch mark reduction compared to pre-treatment photographs. The range of each subscale is between 4-26. A higher value represents a worse outcome. A value of 26 is the maximum score and represents the worst outcome. A value of 4 is the minimum score and represents the best outcome. Subscales are then summed to compute a total score.
Conditions Studied
Interventions
- DRUG Poly-L Lactic Acid
- DEVICE Fractional laser treatment
Study Locations (1)
Michigan
- Henry Ford Health System - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2019-07-15 |
| Est. Completion | 2021-01-31 |
| Phase | Early Phase 1 |
What the finished NCT03858543 record still lists
NCT03858543 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (81% lower).
The record links to 1 condition, with Striae Distensae appearing as the primary indexed condition, and to 2 interventions - of which Poly-L Lactic Acid is the first listed.
NCT03858543 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT03858543 about?
NCT03858543 is a clinical study titled "Fractional Laser Assisted Delivery of Sculptra® for the Treatment of Striae". This study evaluates the efficacy of treatment of striae distensae using the combined modality of fractional laser and poly-L lactic acid (Sculptra).
What is the current status of trial NCT03858543?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 10 participants. The study started on 2019-07-15. Estimated completion is 2021-01-31.
What conditions does trial NCT03858543 study?
This clinical trial studies the following conditions: Striae Distensae.
What interventions are being tested in trial NCT03858543?
The interventions under investigation include: Poly-L Lactic Acid (DRUG), Fractional laser treatment (DEVICE).
Who is sponsoring clinical trial NCT03858543?
This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03858543 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03858543's enrollment target sits among peer trials
10 1629th of 2000 higher than 256 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI